# Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

> **NCT06248606** · PHASE2 · RECRUITING · sponsor: **Ryan Gentzler, MD** · enrollment: 30 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- NSCLC
- KRAS G12C

## Interventions

- **DRUG:** Adagrasib
- **RADIATION:** Stereotactic Radiosurgery

## Key facts

- **NCT ID:** NCT06248606
- **Lead sponsor:** Ryan Gentzler, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-06
- **Primary completion:** 2027-02-25
- **Final completion:** 2028-02-25
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06248606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06248606, "Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06248606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*